1. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
    Masaki Shimoji et al, 2016, Lung Cancer CrossRef
  2. Biomarkers of response to immune checkpoint blockade in cancer treatment
    Takeo Fujii et al, 2018, Critical Reviews in Oncology/Hematology CrossRef
  3. Immunothérapie dans le cancer bronchique non à petites cellules : inhibition de la voie PD1/PDL1
    L. Guilleminault et al, 2015, Revue de Pneumologie Clinique CrossRef
  4. Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1
    Matti Ullah et al, 2020, Cancers CrossRef
  5. PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer
    HIDEFUMI SASAKI et al, 2014, Molecular and Clinical Oncology CrossRef
  6. PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells
    null Inoue et al, 2019, Cancers CrossRef
  7. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
    Robert Brody et al, 2017, Lung Cancer CrossRef
  8. Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
    Kristin J. Lastwika et al, 2016, Cancer Research CrossRef
  9. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations
    Barbora Brodská et al, 2019, International Journal of Molecular Sciences CrossRef
  10. Update on Immune Checkpoint Inhibitors in Lung Cancer
    Benjamin C. Creelan, 2014, Cancer Control CrossRef